Anticoagulants in the Treatment of Renal Disease
Authors: VICTOR E. POLLAK
Journal: Annals of Internal Medicine (1970)

Editorial Notes1 August 1970Anticoagulants in the Treatment of Renal DiseaseVICTOR E. POLLAK, M.D., F.A.C.P.VICTOR E. POLLAK, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-73-2-334 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThat glomerulonephritis can be produced experimentally by immunologic mechanisms is now well known, and there is much evidence to suggest that similar mechanisms are responsible for some types of glomerular disease in man (1). More recent is the view that coagulation within the glomerular capillaries may play an important role in the pathogenesis of certain types of glomerular changes. This view is based on the demonstration of fibrinogen derivatives and of fibrin and platelet thrombi in the kidney and particularly within the glomerular capillaries (2-5). Increasing evidence supports the occurrence in some renal diseases of products of fibrin breakdown in...References1. MCCLUSKEYVASSALLI RP: Experimental glomerular diseases, in The Kidney. Morphology, Biochemistry, Physiology, vol. II, edited by ROUILLER C and MULLER AF, New York, Academic Press, Inc., Publishers, 1969, pp. 84-189 Google Scholar2. SIMONCHATELANAT GF: Fibrine et fibrinoïde dans les glomérulopathies. Étude comparée en pathologie expérimentale et spontanée. Path Microbiol (Basel) 26:191-205, 1963 Google Scholar3. VASSALLIMCCLUSKEY PR: The coagulation process and glomerular disease. Amer J Med 39:179-183, 1965 CrossrefMedlineGoogle Scholar4. KOFFLERPARONETTO DF: Fibrinogen deposition in acute renal failure. Amer J Path 49:383-391, 1966 MedlineGoogle Scholar5. MCCLUSKEYVASSALLIGALLO RPA: An immunofluorescent study of pathogenetic mechanisms in glomerular disease. New Eng J Med 274:695-701, 1966 CrossrefMedlineGoogle Scholar6. STIEHMTRYGSTAD EC: Split products of fibrin in human renal disease. Amer J Med 46:774-786, 1969 CrossrefMedlineGoogle Scholar7. LINTONGAVRASGLEADLE AHR: Microangiopathic haemolytic anaemia and the pathogenesis of malignant hypertension. Lancet 1:1277-1282, 1969 CrossrefMedlineGoogle Scholar8. HALPERNMILLIEZLAGRUE BPG: Protective action of heparin in experimental immune nephritis. Nature (London) 205:257-259, 1965 CrossrefMedlineGoogle Scholar9. HUMAIRKWAANPOTTER LHE: The role of fibrinogen in renal disease. II. Effect of anticoagulants and urokinase on experimental lesions in mice. J Lab Clin Med 74:72-78, 1969 MedlineGoogle Scholar10. SCHÜTTERLEPLATT GD: Die Beeinflussung der experimentellen Glomerulonephritis durch Heparin und Prednisolon. Klin Wschr 48:179-182, 1970 CrossrefMedlineGoogle Scholar11. VASSALLIMCCLUSKEY PR: The pathogenetic role of the coagulation process in rabbit masugi nephritis. Amer J Path 45:653-666, 1964 MedlineGoogle Scholar12. KINCAID-SMITHSAKERFAIRLEY PBK: Anticoagulants in "irreversible" acute renal failure. Lancet 2:1360-1363, 1968 CrossrefMedlineGoogle Scholar13. KINCAID-SMITHLAVERFAIRLEY PMK: Dipyridamole and anticoagulants in renal disease due to glomerular and vascular lesions: a new approach to therapy. Med J Aust 1:145-151, 1970 CrossrefMedlineGoogle Scholar14. EMMONSHARRISONHONOUR PMA: Effect of dipyridamole on human platelet behaviour. Lancet 2:603-606, 1965 CrossrefMedlineGoogle Scholar15. SULLIVANHARKENGORLIN JDR: Effect of dipyridamole on the incidence of arterial emboli after cardiac valve replacement. Circulation 39 & 40 (suppl I):149-153, 1969 Google Scholar16. BRAINDACIEHOURIANE MJD: Microangiopathic haemolytic anaemia: the possible role of vascular lesions on pathogenesis. Brit J Haemat 8:358-374, 1962 CrossrefMedlineGoogle Scholar17. MCMILLAN R: Heparin in delayed transplant function. Lancet 1:1178-1180, 1968 CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Department of Medicine Michael Reese Hospital Medical Center Chicago, Ill. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByThromboprophylactic Effect of Ticlopidine in Arteriovenous Fistulas for HaemodialysisCLINICAL USE OF HEPARIN AND HEPARINOIDS, EXCLUDING THE TREATMENT OF THROMBOEMBOLISMDelayed Hypersensitivity in Man: Effects of Systemic AnticoagulationProphylaxe und Therapie der Shuntthrombose bei terminaler NiereninsuffizienzDrug Selection and Dosage in Renal Insufficiency 1 August 1970Volume 73, Issue 2Page: 334-335KeywordsAnticoagulantsCapillariesFibrinFibrinogenGlomerulonephritisKidneysPathogenesisPlateletsRenal diseases Issue Published: 1 August 1970 PDF DownloadLoading ...